|
|
Сonditions and diseases
ALS Alzheimer's Disease Anemia Anti-Aging Treatment Arterial Hypertension Autism Cancer Diabetes Treatment Eye Diseases HIV/AIDS Idiopathic Encephalopathy Ischemic Heart Disease Liver Diseases MD Treatment Multiple Sclerosis Treatment Parkinson Treatment Rheumatoid Arthritis SMA Ulcerative Colitis. Crohn’s Disease
News about stem cells
Stem Cell Therapy Cures Type 1 Diabetes in Mice
10 June 2013
Using an immune-suppressing medication and adult stem cells from healthy donors, researchers say they were able to cure type 1 diabetes in mice.
10 June 2013
Using an immune-suppressing medication and adult stem cells from healthy donors, researchers say they were able to cure type 1 diabetes in mice.
Stem cell injections improve spinal injuries in rats
30 May 2013
An international team led by researchers at the University of California reports that a single injection of human neural stem cells produced neuronal regeneration and improvement of function and mobility in rats impaired by an acute spinal cord injury.
30 May 2013
An international team led by researchers at the University of California reports that a single injection of human neural stem cells produced neuronal regeneration and improvement of function and mobility in rats impaired by an acute spinal cord injury.
Cloning Is Used to Create Embryonic Stem Cells
19 May 2013
Scientists have finally succeeded in using cloning to create human embryonic stem cells, a step toward developing replacement tissue to treat diseases.
All news
19 May 2013
Scientists have finally succeeded in using cloning to create human embryonic stem cells, a step toward developing replacement tissue to treat diseases.
2013 Smart Guide: Revolutionary human stem cell trial
If all goes to plan, 2013 should see the first human trial of "rewound" cells. These are produced by turning adult cells back to a stem cell state and then coaxing them into becoming another type of cell. It will mark a milestone in our ability to generate new tissue - and maybe whole organs - from people's own cells.
In 2006, Shinya Yamanaka reverted skin cells to an embryonic state. He called these cells induced pluripotent stem cells. iPSCs can grow into any tissue in the body by exposure to natural growth factors.
The long-term goal of the pioneering trial of iPSC-derived cells is to provide blood platelets to people undergoing cancer therapy, who need platelet transfusions to repair damaged tissues and prevent uncontrolled bleeding. Initially, however, platelets grown from iPSC will be given to healthy volunteers. Researchers in charge of the proposed trial, planned by Advanced Cell Technology (ACT) of Marlborough, Massachusetts, want to ensure that the cells are well tolerated before moving on to people with cancer and other blood-related conditions.
Some studies of iPSCs have suggested that they may have a higher risk of becoming cancerous. "Since platelets don't have nuclei they can't form tumours, which makes them ideal for the first iPSC clinical trial," says Robert Lanza, chief medical officer at ACT.
Volunteers will be given platelets made from pre-existing stocks of iPSCs, but if the trial goes well, Lanza says they will create platelets from cancer patients' own cells.
In 2006, Shinya Yamanaka reverted skin cells to an embryonic state. He called these cells induced pluripotent stem cells. iPSCs can grow into any tissue in the body by exposure to natural growth factors.
The long-term goal of the pioneering trial of iPSC-derived cells is to provide blood platelets to people undergoing cancer therapy, who need platelet transfusions to repair damaged tissues and prevent uncontrolled bleeding. Initially, however, platelets grown from iPSC will be given to healthy volunteers. Researchers in charge of the proposed trial, planned by Advanced Cell Technology (ACT) of Marlborough, Massachusetts, want to ensure that the cells are well tolerated before moving on to people with cancer and other blood-related conditions.
Some studies of iPSCs have suggested that they may have a higher risk of becoming cancerous. "Since platelets don't have nuclei they can't form tumours, which makes them ideal for the first iPSC clinical trial," says Robert Lanza, chief medical officer at ACT.
Volunteers will be given platelets made from pre-existing stocks of iPSCs, but if the trial goes well, Lanza says they will create platelets from cancer patients' own cells.